Indication
Treatment of osteoporosis in post-menopausal women at increased risk of fracture. A reduction in the risk of vertebral fractures has been demonstrated. Efficacy on femoral-neck fractures has not been established.
Loading your page…
Loading your page…
Osteoporosis, Postmenopausal
Marketing Authorisation Holder: Roche Registration Ltd.
EMA Authorisation: 23/02/2004
INN: ibandronic acid
AI Drug & Interaction Analysis
Free account required
Ask Osler about Bondenza (previously Ibandronic Acid Roche): drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.